首页> 外文期刊>Heartdrug: excellence in cardiovascular trials >Nitric Oxide Synthase Inhibitors in Refractory Cardiogenic Shock due to Myocardial Infarction after Percutaneous Coronary Intervention
【24h】

Nitric Oxide Synthase Inhibitors in Refractory Cardiogenic Shock due to Myocardial Infarction after Percutaneous Coronary Intervention

机译:经皮冠状动脉干预后,由于心肌梗塞引起的难治性心源性休克中的一氧化氮合酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

ST-elevation myocardial infarction complicated by cardiogenic shock (CS), warrants optimal medical support and urgent revascularization usually by percutaneous coronary intervention (PCI). However, contemporary studies repdrt that half of these post-PCI patients will succumb to intractable heart stunning, failure, and death. Most of those who survive, however, become asymptomatic or mildly symptomatic. We discuss current definitions of CS, and pump function, as well as the potential deleterious effects of nitric oxide on the stunned and failing heart. We review the studies employing nitric oxide synthase inhibitors for post-PCI cardiogenic shock, and point out future studies.
机译:心脏源性休克(CS)复杂的st-Elevation心肌梗死,保证通常由经皮冠状动脉介入干预(PCI)的最佳医疗支持和紧急的血运重建。 然而,当代研究表明,这些后PCI后患者中有一半会屈服于令人难以置信的心脏令人惊叹,失败和死亡。 然而,大多数生存的人都变得无症状或轻度症状。 我们讨论了CS和泵功能的当前定义,以及一氧化氮对震惊和失败心脏的潜在有害影响。 我们回顾了采用一氧化氮合酶抑制剂进行PCI后心源性休克的研究,并指出未来的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号